SCHEMBL10065443

SCHEMBL10065443

CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)O)cc3OC)cc2N1CCC(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 17/20 0.52
BRD4 O60885 13/20 0.52
PLK3 Q9H4B4 7/20 0.47
PLK2 Q9NYY3 5/20 0.47
PTK2 Q05397 4/20 0.47
PRKD3 O94806 3/20 0.47
CLK2 P49760 3/20 0.47
CAMK2G Q13555 3/20 0.47
CAMK2D Q13557 3/20 0.47
PRKD2 Q9BZL6 3/20 0.47
CSNK1G1 Q9HCP0 3/20 0.47
CSNK1G3 Q9Y6M4 3/20 0.47
MAP4K4 O95819 2/20 0.47
PRKCG P05129 2/20 0.47
RPS6KA3 P51812 2/20 0.47
NEK4 P51957 2/20 0.47
SRPK1 Q96SB4 1/20 0.47
ALK Q9UM73 4/20 0.44
BRDT Q58F21 3/20 0.44
DAPK3 O43293 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10065440 0.90 BRD4 (0.46) PLK1BRD4RPS6KA3BRDTTAF1
SCHEMBL10065441 0.86 RPS6KA3 (0.44) PLK1BRD4PLK3PLK2RPS6KA3
SCHEMBL861947 0.85 PLK1 (0.68) PLK1BRD4PLK3PLK2PTK2
SCHEMBL21916321 0.85 PLK1 (0.68) PLK1BRD4PLK3PLK2PTK2
SCHEMBL10065439 0.81 PLK1 (0.41) PLK1BRD4PLK3PLK2PTK2
SCHEMBL10081358 0.81 MEN1 (0.41) PLK1BRD4PLK3PLK2PTK2
SCHEMBL10065446 0.79 BRD4 (0.56) PLK1BRD4BRDTTAF1
SCHEMBL21527053 0.77 RPS6KA3 (0.62) PLK1BRD4PLK3PLK2RPS6KA3
SCHEMBL862198 0.77 RPS6KA3 (0.62) PLK1BRD4PLK3PLK2RPS6KA3
SCHEMBL12323787 0.76 PLK1 (0.78) PLK1BRD4PLK3PLK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1768981-B1 NOVEL PYRIDODIHYDROPYRAZINONES METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2012-09-12 EP disclosed
US-8193188-B2 Methods of using pyridodihydropyrazinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-05 US disclosed
US-8193188-B2 Methods of using pyridodihydropyrazinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-05 US disclosed
US-20100029642-A1 Methods of Using Pyridodihydropyrazinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-04 US disclosed
US-20100029642-A1 Methods of Using Pyridodihydropyrazinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-04 US disclosed
US-7625899-B2 Pyridodihydropyraziones, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-01 US disclosed
US-7625899-B2 Pyridodihydropyraziones, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029642-A1 Methods of Using Pyridodihydropyrazinones CYP2D6, CYP2B6, C5 PLK1 1023/4885BRD4 1717/4885PLK3 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.